Tag: DESTINY-Breast

Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06

Expert
Prof. Giuseppe Curigliano, University of Milan, Italy
Trial
Phase 3, DESTINY-Breast06
Conference
ASCO 2024

24 June 2024 15:38

Trastuzumab deruxtecan effective in both second-line and neoadjuvant setting

Presented By
Dr Ian Krop (Yale Cancer Center, CT, USA); Prof. Sara Hurvitz (David Geffen School of Medicine, CA, USA); Prof. Aditya Bardia (Harvard Medical School, MA, USA)
Trial
Phase 3, DESTINY-Breast02; DESTINY-Breast03; TRIO-US B-12 TALENT
Conference
SABCS 2022
Type
Peer-reviewed article

1 February 2023 17:51

Practice-changing results of T-DXd in HER2-low breast cancer 

Presented By
Prof. Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA
Trial
Phase 3, DESTINY-Breast04
Conference
ASCO 2022
Type
Peer-reviewed article

5 August 2022 12:04

Trastuzumab deruxtecan outperforms trastuzumab emtansine

Presented By
Dr Sara Hurvitz, University of California, CA, USA
Trial
Phase 3, DESTINY-Breast03
Conference
SABCS 2021
Type
Peer-reviewed article

31 January 2022 18:02

SABCS 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
SABCS 2021

10 January 2022 20:59

Trastuzumab deruxtecan triples PFS

Presented By
Dr Javier Cortés, International Breast Cancer Center Barcelona, Spain
Trial
Phase 3, DESTINY-Breast03
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:51

Second-line trastuzumab deruxtecan for metastatic HER2-positive breast cancer: Interview with Javier Cortés

Expert
Prof. Javier Cortés , Vall d’Hebron Institute of Oncology, Barcelona, Spain
Trial
Phase 3, DESTINY-Breast03
Conference
ESMO 2021

12 October 2021 10:31

ESMO 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Trial
DESTINY-Breast03, MONALEESA-2, KEYNOTE-716, CASPIAN, CheckMate-649, Impower010
Conference
ESMO 2021

4 October 2021 09:27

Trastuzumab-deruxtecan showed clinical activity in patients with brain metastases

Presented By
Prof. Guy Jerusalem , CHU Liège, Belgium
Trial
Phase 2, DESTINY-Breast01
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 19:54

T-DXd response on brain metastases in HER2+ breast cancer patients

Presented By
Prof. Guy Jerusalem, Liège University, Belgium
Trial
Phase 2, DESTINY-Breast01
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 11:48

T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Presented By
Dr Fabrice André, Institut Gustave Roussy, Paris, France
Trial
Phase 2, DESTINY-Breast07
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 10:55

SABCS 2020: Update from the DESTINY-Breast01 trial

Presented By
Dr Shanu Modi , Memorial Sloan Kettering Cancer Center
Trial
DESTINY-Breast01
Journal
Physician's Weekly
Conference
SABCS 2020

13 April 2021 18:50

SABCS 2020: Adding nivolumab to trastuzumab deruxtecan is well tolerated

Presented By
Erika Hamilton, Sarah Cannon Research Institute at Tennessee Oncology in Nashville, TN
Trial
DESTINY-Breast01
Conference
SABCS 2020

13 April 2021 17:11

HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients

Trial
Phase 2, DESTINY-Breast01
Conference
SABCS 2019
Type
Peer-reviewed article

13 February 2020 22:54
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com